Preprint: An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimer’s disease.

Lizama B, North H, Pandey K, Williams C, Duong D, Cho E, Caro VD, Ping L, Blennow K, Zetterberg H, Lah J, Levey A, Grundman M, Caggiano A, Seyfried N, Hamby M. An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimer’s disease. bioRxiv. 2024:2024.02.16.578765. doi: 10.1101/2024.02.16.578765.